Biblio Discovery — Demo Discovery Service

23 hasil untuk "Thomas, Sachdev"

Menampilkan 1–20 · 2,42 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer

    Sweis, Randy F; Thomas, Sachdev; Bank, Bruce dkk.

    Cureus · 2016 · Inggris · PubMed Central

    Epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) rearrangements are now routine biomarkers that have been incorporated into the practice of managing non-small cell lung cancer (NSCLC). Historically, the two molecular alterations have been viewed as…

  2. Artikel Jurnal Teks lengkap

    A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer

    Lee, Richard T.; Beekman, Kathleen E.; Hussain, Maha dkk.

    Clin Genitourin Cancer · 2008 · Inggris · PubMed Central

    BACKGROUND: Advanced renal cell cancer (RCC) continues to have a poor overall prognosis despite new FDA-approved therapies. Although taxane-based therapies are generally ineffective in RCC, research into the role of the von Hippel-Lindau protein has shown an association with microtubule dynamics…

  3. Artikel Jurnal Teks lengkap

    Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies

    Pan, Minggui; Jiang, Chen; Zhang, Zheyang dkk.

    Cancers (Basel) · 2023 · Inggris · PubMed Central

    SIMPLE SUMMARY: SMARCA4-mutated tumors are associated with poor prognosis. However, it is not clear if male and female patients have the same or different prognosis and if additional common mutations within the tumor play a role in prognosis. We have found that male patients had substantially worse…

  4. Artikel Jurnal Teks lengkap

    PHASE I ADJUVANT RADIATION WITH DOCETAXEL IN HIGH RISK HEAD AND NECK CANCER

    Clark, Joseph I.; Eisner, Robert M.; Hofmeister, Craig dkk.

    Am J Clin Oncol · 2009 · Inggris · PubMed Central

    BACKGROUND: This phase I study was designed to determine the maximum tolerated dose (MTD) and preliminary efficacy of docetaxel with concurrent radiotherapy, (RT), in high risk squamous cell carcinoma of the head and neck (HNSCC). PATIENTS AND METHODS: Eligible patients had resected HNSCC…

  5. Artikel Jurnal Teks lengkap

    A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

    Traynor, Anne M.; Lee, Ju-Whei; Bayer, Gerald K. dkk.

    Invest New Drugs · 2009 · Inggris · PubMed Central

    BACKGROUND: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. METHODS: Triapine 105 mg/m(2) IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m(2) on days 1, 8, and 15, of a 28 day cycle. RESULTS: Eighteen patients…

  6. Artikel Jurnal Teks lengkap

    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

    Hines, Stephanie L.; Mincey, Betty Anne; Sloan, Jeff A. dkk.

    J Clin Oncol · 2008 · Inggris · PubMed Central

    PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer. PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer…

  7. Artikel Jurnal Teks lengkap

    Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)

    Rosenbaum, Cara A.; Jung, Sin-Ho; Pitcher, Brandelyn dkk.

    Br J Haematol · 2019 · Inggris · PubMed Central

    Rituximab monotherapy has proven efficacy in treatment-naïve, asymptomatic advanced-stage follicular lymphoma (FL). Ofatumumab is a fully humanized anti-CD20 monoclonal antibody with increased CD20 affinity and complement-dependent cytotoxicity. This phase 2 trial (NCT01190449) evaluated ofatumumab…

  8. Artikel Jurnal Teks lengkap

    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

    Ramalingam, Suresh S.; Maitland, Michael L.; Frankel, Paul dkk.

    J Clin Oncol · 2009 · Inggris · PubMed Central

    PURPOSE: Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone–mediated mechanisms. It also enhances the anticancer effects of platinum compounds and taxanes in non–small-cell lung cancer (NSCLC) cell lines. This phase II randomized, double-blinded…

  9. Artikel Jurnal Teks lengkap

    Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

    Wolf, Sherry L.; Qin, Rui; Menon, Smitha P. dkk.

    J Clin Oncol · 2010 · Inggris · PubMed Central

    PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated. This trial was conducted on the basis of preliminary data that a urea/lactic acid–based topical keratolytic agent (ULABTKA) may prevent…

  10. Artikel Jurnal Teks lengkap

    Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)

    Ready, Neal E.; Pang, Herbert H.; Gu, Lin dkk.

    J Clin Oncol · 2015 · Inggris · PubMed Central

    PURPOSE: To evaluate the efficacy of maintenance sunitinib after chemotherapy for small-cell lung cancer (SCLC). PATIENTS AND METHODS: The Cancer and Leukemia Group B 30504 trial was a randomized, placebo-controlled, phase II study that enrolled patients before chemotherapy (cisplatin 80 mg/m(2) or…

  11. Artikel Jurnal Teks lengkap

    NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status

    Dy, Grace K.; Molina, Julian R.; Qi, Yingwei dkk.

    J Thorac Oncol · 2014 · Inggris · PubMed Central

    PURPOSE: We hypothesized that the combination of bevacizumab, carboplatin and pemetrexed will be an effective first-line regimen in fit, elderly patients with nonsquamous NSCLC. PATIENTS AND METHODS: Treatment-naïve, stage IIIB/IV nonsquamous NSCLC patients ≥ 70 years old with good performance…

  12. Artikel Jurnal Teks lengkap

    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

    Campbell, Nicholas P.; Kunnavakkam, Rangesh; Leighl, Natasha dkk.

    Lung Cancer · 2012 · Inggris · PubMed Central

    INTRODUCTION: Malignant mesothelioma (MM) is an aggressive disease with limited therapeutic options. In preclinical models, vascular endothelial growth factor (VEGF) stimulates MM proliferation. In MM patients, higher plasma VEGF levels correlate inversely with survival. Cediranib is an orally…

  13. Artikel Jurnal Teks lengkap

    TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer

    Pan, Minggui; Jiang, Chen; Tse, Pam dkk.

    J Clin Oncol · 2021 · Inggris · PubMed Central

    PURPOSE: To examine the association of gain-of-function (GOF) and non–gain-of-function (non-GOF) TP53 mutations with prognosis of metastatic right-sided (RCC) versus left-sided colorectal cancer (LCC). METHODS: This cohort study included patients with metastatic colorectal cancer (CRC) who had…

  14. Artikel Jurnal Teks lengkap

    Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma

    Pan, Minggui; Zhou, Maggie Yuxi; Jiang, Chen dkk.

    Clin Cancer Res · 2023 · Inggris · PubMed Central

    PURPOSE: To examine whether overall survival (OS) differs for male and female patients with advanced soft-tissue sarcoma (STS). EXPERIMENTAL DESIGN: The study included patients from Kaiser Permanente Northern California and Stanford Cancer Center with grade 2 and 3 locally advanced or metastatic…

  15. Artikel Jurnal Teks lengkap

    PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma

    Pan, Minggui; Zhou, Maggie Y.; Jiang, Chen dkk.

    BJC Rep · 2024 · Inggris · PubMed Central

    BACKGROUND: We aimed to examine whether PTEN pathogenic variants (mutPTEN) were associated with overall survival (OS) in patients with advanced soft tissue sarcoma (STS) with the presence of one or more of the most common genomic alterations including p53, CDKN2A, RB1, and ATRX pathogenic variants…

  16. Artikel Jurnal Teks lengkap

    Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)()

    Jatoi, Aminah; Dakhil, Shaker R.; Foster, Nathan R. dkk.

    J Thorac Oncol · 2008 · Inggris · PubMed Central

    PURPOSE: This study was undertaken to explore the response rate of a first-line, three-drug regimen that consisted of bortezomib, paclitaxel, and carboplatin in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia. PATIENTS AND METHODS: Patients…

  17. Artikel Jurnal Teks lengkap

    Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas

    Pan, Minggui; Dang, Arun; Huang, Tina dkk.

    BJC Rep · 2025 · Inggris · PubMed Central

    BACKGROUND: Advanced esophageal (EAC), gastroesophageal junction (GEJAC) and gastric (GAC) adenocarcinomas with HER2 amplification or overexpression (HER2+) are routinely treated with trastuzumab. However, it remains unclear if HER2+ is associated with superior overall survival (OS). METHODS: The…

  18. Artikel Jurnal Teks lengkap

    Sex disparity in survival outcomes of advanced gastric adenocarcinoma

    Pan, Minggui; Tong, Meng M.; Stover, Jack dkk.

    BJC Rep · 2025 · Inggris · PubMed Central

    PURPOSE: To examine potential overall survival (OS) differences between males and females with advanced gastric (GAC), gastroesophageal junction (GEJAC) and esophageal (EAC) adenocarcinoma. PATIENTS AND METHODS: The study included patients from Kaiser Permanente Northern California with de novo…

  19. Artikel Jurnal Teks lengkap

    A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321

    Zhao, Yujie; Foster, Nathan R.; Meyers, Jeffrey P. dkk.

    J Thorac Oncol · 2015 · Inggris · PubMed Central

    INTRODUCTION: Despite the advances in radiation techniques and chemotherapy, survival with current platinum-based chemotherapy and concomitant thoracic radiation remains dismal. Bortezomib, a proteasome inhibitor, modulates apoptosis and cell cycle through disruption of protein degradation. The…

  20. Artikel Jurnal Teks lengkap

    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

    Edelman, Martin J.; Wang, Xiaofei; Hodgson, Lydia dkk.

    J Clin Oncol · 2017 · Inggris · PubMed Central

    PURPOSE: Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B (CALGB) 30203, we found that the selective COX-2 inhibitor celecoxib in addition to chemotherapy in advanced NSCLC improved…